Welcome to LookChem.com Sign In|Join Free
  • or
Phenol, 5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methyl- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

423170-26-7

Post Buying Request

423170-26-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

423170-26-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 423170-26-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,2,3,1,7 and 0 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 423170-26:
(8*4)+(7*2)+(6*3)+(5*1)+(4*7)+(3*0)+(2*2)+(1*6)=107
107 % 10 = 7
So 423170-26-7 is a valid CAS Registry Number.

423170-26-7Relevant academic research and scientific papers

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity

Newton, Rebecca,Bowler, Katherine A.,Burns, Emily M.,Chapman, Philip J.,Fairweather, Emma E.,Fritzl, Samantha J.R.,Goldberg, Kristin M.,Hamilton, Niall M.,Holt, Sarah V.,Hopkins, Gemma V.,Jones, Stuart D.,Jordan, Allan M.,Lyons, Amanda J.,Nikki March,McDonald, Neil Q.,Maguire, Laura A.,Mould, Daniel P.,Purkiss, Andrew G.,Small, Helen F.,Stowell, Alexandra I.J.,Thomson, Graeme J.,Waddell, Ian D.,Waszkowycz, Bohdan,Watson, Amanda J.,Ogilvie, Donald J.

, p. 20 - 32 (2016/02/19)

Deregulation of the receptor tyrosine kinase RET has been implicated in medullary thyroid cancer, a small percentage of lung adenocarcinomas, endocrine-resistant breast cancer and pancreatic cancer. There are several clinically approved multi-kinase inhibitors that target RET as a secondary pharmacology but additional activities, most notably inhibition of KDR, lead to dose-limiting toxicities. There is, therefore, a clinical need for more specific RET kinase inhibitors. Herein we report our efforts towards identifying a potent and selective RET inhibitor using vandetanib 1 as the starting point for structure-based drug design. Phenolic anilinoquinazolines exemplified by 6 showed improved affinities towards RET but, unsurprisingly, suffered from high metabolic clearance. Efforts to mitigate the metabolic liability of the phenol led to the discovery that a flanking substituent not only improved the hepatocyte stability, but could also impart a significant gain in selectivity. This culminated in the identification of 36; a potent RET inhibitor with much improved selectivity against KDR.

QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS

-

Page/Page column 68, (2010/02/14)

The present invention provides for compounds with the general formula: A compound of formula (1) having the structure (1) wherein Z is a radical selected from the group (a), (b), or (c) as well as methods and compositions containing these compounds useful

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 423170-26-7